secwatch.observer — SEC 8-K summary
======================================

Issuer:     Camp4 Therapeutics Corp (CAMP)
CIK:        0001736730
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0001736730-25-000021
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CAMP4 reports FY2024 net loss $51.8M; cash $64M, Phase 1 data expected Q4 2025
------------------------------------------------------------------------------

- Net loss of $51.8M for FY2024 vs $49.3M in FY2023; R&D expenses $38.8M, G&A $14.9M.
- Cash and equivalents $64.0M as of Dec 31, 2024; sufficient to fund into Q2 2026.
- Phase 1 trial of CMP-CPS-001 for UCDs ongoing; SAD completed safely, MAD dosing in progress; safety, PK, PD data expected Q4 2025.
- Phase 1b trial in female OTC heterozygotes expected Q2 2025 in Australia, Europe to follow.
- Development candidate CMP-SYNGAP-01 nominated for SYNGAP1-related disorders; GLP tox studies planned 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736730/000173673025000021/0001736730-25-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736730/000173673025000021/camp-20250327.htm
  HTML page:      https://secwatch.observer/filing/0001736730-25-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer